Continuing Education Webinars - On Demand

This webinar will highlight updates in cancer treatment associated with genomic and genetic testing and address challenges and benefits of improving clinical trial enrollment for patients with hereditary cancer.

1. Summarize tumor BRCA mutations and their implications in treatments beyond ovarian cancer.
2. Examine barriers to enrolling individuals with inherited mutations into clinical research.
3. Identify resources available to address challenges in engagement and clinical trial enrollment.

This webinar will examine the American Society of Breast Surgeons (ASBrS) consensus guidelines on genetic testing for all patients with breast cancer and discuss its implications on local and systemic treatment recommendations.

1. Summarize the American Society of Breast Surgeons’ Consensus Guideline on Genetic Testing for Hereditary Breast Cancer and discuss implications to clinical practice.
2. Examine recent literature that supports the ASBrS Consensus Guideline on Genetic Testing for Hereditary Breast Cancer in comparison to current NCCN guidelines.

This webinar will outline various disparities in hereditary cancer care and highlight tools, methods, and focused efforts to improve care delivery and reduce barriers in this patient population.

1. Identify underlying social determinants of health that impact barriers in clinical genetics and hereditary cancer care.
2. Examine provider-oriented obstacles in accessing genetic services and discuss strategies for empowering patients/families and providers to overcome these barriers.
3. Evaluate racial disparities in BRCA testing and discuss focused efforts to improve care delivery.

This webinar will summarize highlights from recent 2021 virtual meetings of the Society of Gynecologic Oncology and the National Consortium of Breast Centers, focusing on evolving strategies in hereditary breast and ovarian cancer.

1. Examine targeted therapies in hereditary ovarian cancer and strategies to manage treatment side effects.
2. Identify current recommendations for screening, risk reduction and safety/efficacy of exogenous hormones in individuals with a moderate to high risk for breast & ovarian cancer.
3. Define key components for a comprehensive high-risk clinic.
4. Summarize the current guidelines for endocrine therapy in patients with germline BRCA mutations and the potential for polygenic risk scores (PRS) as a stratification tool to guide endocrine therapy in patients with hereditary and high-risk familial breast cancer.

This webinar will focus on evolving strategies in hereditary colorectal cancer. Program presentations will highlight novel therapies for risk reduction, additional genes and associated cancer risks as well as discuss the role of polygenic risk scores to identify and stratify colorectal cancer risks.

1. Evaluate current data and guidelines related to aspirin as chemoprevention in individuals with Lynch and discuss implementation of an aspirin chemoprevention regiment from a clinical perspective.
2. Summarize findings from an analysis of colon and other cancer risks for monoallelic MUTYH and monoallelic NTHL1 carriers identified by multi-gene panel testing.
3. Examine current scientific data as it pertains to polygenic risk scores (PRS) and colorectal cancer (CRC)
   • Discuss identification and weighting of single nucleotide variants (SNV)
   • Evaluate additional cancer risk factors including, lifestyle, family history and ancestry challenges
   • Compare PRS vs single gene cancer risks related to colorectal cancer